Munich, Bayern, GermanyFounded 20255+ employeesPrivate
$5.9M raisedSeed· last: seed (Dec 2025)· 1 rounds
Backed by(5 investors)
Amplifold develops the next generation of rapid tests using DNA origami nanotechnology – tiny structures made from DNA that we design to detect specific molecules with extremely high accuracy. This allows us to identify diseases and biomarkers 100 times more accurately than today’s best rapid tests. We are a passionate team of scientists and molecular engineers, driven by the excitement of innovation, applying cutting-edge nanotechnology, molecular biology, and diagnostics to transform early detection, treatment decisions, and global health.
